Treatment with MAP4K4 inhibitor GNE-495 reduced these tumor-promoting activities associated with MLK3 phosphorylation in vitro, and reduced tumor weight and MAP4K4 and MLK3 expression in vivo (78). Here, MAP3K11 is linked to neoplasm.